The Role of Ambulatory Oxygen in Improving the Effectiveness of Pulmonary Rehabilitation for COPD Patients

March 3, 2021 updated by: Imperial College Healthcare NHS Trust

The Role of Ambulatory Oxygen in Improving the Effectiveness of Pulmonary Rehabilitation for Chronic Obstructive Pulmonary Diseases Patients

Pulmonary rehabilitation (PR) is an exercise program tailored for patients with chronic lung disease that is a core part of the management of patients with Chronic Obstructive Pulmonary Disease (COPD). Many COPD patients develop low oxygen levels (desaturation) during exercise and this is often discovered when they are being evaluated for PR. Current practice is to administer oxygen to COPD patients with exercise-induced desaturation, but this is based on very limited evidence. This limited evidence relates to a short-term increase in exercise capacity and it is not known if this translates into longer term increases in activity or whether providing these patients with oxygen improves outcomes after PR.

In addition it is not known if patients given ambulatory oxygen continue to use it after completing PR. Evidence for a beneficial effect of oxygen would provide a more solid evidence base for its use. Conversely demonstration of no effect would allow reassessment of the use of oxygen and whether the costs are justified. Therefore the aims of this study are to assess the effects of oxygen on outcomes from PR and assess the usage of ambulatory oxygen following completion of PR.

Study Overview

Status

Terminated

Intervention / Treatment

Detailed Description

The study will be a randomised, single-blinded study comparing oxygen with air in Chronic Obstructive Pulmonary Disease (COPD) patients undergoing Pulmonary Rehabilitation (PR).

The study subjects will be patients with a confirmed diagnosis of COPD who have been accepted for PR and who are not hypoxemic at rest, but have exercise-induced desaturation (defined as a fall in oxygen saturations (SaO2) ≥4% to at least <90%, or any fall to a SaO2 <90%) and demonstrate positive improvement with use of ambulatory oxygen as per the British Thoracic Society 2015 Oxygen guidelines. It is standard practice for patients to have this assessment prior to commencing PR and as part of the assessment the flow rate required to increase the SaO2 to ≥90% during exercise will be determined. Patients will be recruited from PR programs at imperial college health care trust hospitals.

The subjects will be randomised to receive either oxygen at the flow rate determined at the initial assessment to a maximum flow rate of 6 litres per minute, or room air. The subjects will then undergo a standard program of PR over 6 - 8 weeks and then undergo reassessment. 20 patients are required in each group to detect a 30% effect size on the 6 minute walk test (6MWT) with 80% power at the 5% significance level and 29 patients in each group to detect a 25% effect with 80% power. Therefore a minimum of 20 patients per group will be included.

Baseline assessments prior to commencing PR will include symptom and quality of life assessments including Borg scale for assessment of breathlessness, Chronic Respiratory Questionnaire (CRQ), COPD Assessment Tool (CAT) and the Hospital Anxiety and Depression score (HAD). A 6 minute walk test (6MWT) will be carried out as this is a widely used and well validated tool to measure exercise capacity. A handheld dynamometer will be used to obtain more detailed measures of quadriceps muscle strength. In addition we will measure activity at home during and after PR using pedometers as this has never been investigated previously.These are simple devices that can be attached to patients and count the numbers of steps during a day and therefore provide an estimate of activity in the home environment. A yamax Digi-walker SW-200 pedometer will be used to count the number of steps taken per day. Patients will be instructed to wear the device on left side of the body all the time, except when sleeping or showering. Pedometer placement was standardised by placing it on the belt or waistband, in the midline of the thigh, consistent with the manufacturers recommendation and with other studies conducted previously. Patients will be record daily step counts on daily diary cards until their final follow up.

The measures of exercise capacity at the follow up assessment will be carried out off oxygen and will be carried out by an observer blinded as to whether they received oxygen or not during PR. All patients will be provided with ambulatory oxygen for domiciliary use after completing PR.

The hypothesis is that use of oxygen in selected patients improves exercise capacity during PR. The measurable aims will be exercise capacity and on-going usage of oxygen in this patient group.

Primary Objective

Assess the effects of ambulatory oxygen on outcomes from Pulmonary Rehabilitation

Secondary Objectives

  1. Assess the proportion of patients that wish to continue to use ambulatory oxygen.
  2. Assess the usage of ambulatory oxygen following completion of Pulmonary Rehabilitation
  3. Assess whether initiation of ambulatory oxygen before or after PR has any influence on adherence to usage at 8 and 12 weeks.

Study Type

Interventional

Enrollment (Actual)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. A confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD)
  2. Fulfil the clinical criteria for Pulmonary Rehabilitation (PR)
  3. Demonstrate exercise-induced desaturation (defined as a fall in SaO2 ≥4% to at least <90%, or any fall to a SaO2 <90%) and demonstrate positive improvement with use of ambulatory oxygen as per the British Thoracic Society 2015 Oxygen Guidelines

Exclusion Criteria:

  1. Use of long term oxygen therapy
  2. Unable to provide informed consent
  3. Significant respiratory disease other than COPD
  4. Any patient needing more than 6 litres per minute oxygen to correct desaturation
  5. Severe desaturation: SaO2 < 80% during 6 Minute Walk Test
  6. Any absolute contraindication to Pulmonary Rehabilitation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Ambulatory oxygen
Patient will use ambulatory oxygen during pulmonary rehabilitation programme (flow rate determined at the initial assessment to a maximum flow rate of 6 litres per minute)
Placebo Comparator: Room air
Patient will breath on room air during pulmonary rehabilitation programme

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Functional Exercise Capacity
Time Frame: 0, 8weeks
6 Minute Walk Test (6MWT)- Distance in meters
0, 8weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of Participants Reporting a Change in the Quality of Life
Time Frame: 0,8weeks
Chronic Respiratory Questionnaire(CRQ)- Number of Participants achieving minimal clinically important difference (MCID) in CRQ compared between baseline and follow up assessment.
0,8weeks
Number of Participants Reporting a Change in Anxiety Score
Time Frame: 0,8weeks
Hospital anxiety and depression score- Anxiety component (HADS-A)-Numbers of participants achieving Minimal clinically important difference in HADS-A compared between baseline and follow up assessment.
0,8weeks
Number of Participants Reporting Change in Depression Score
Time Frame: 0,8weeks
Hospital anxiety and depression score- Depression component (HADS-D)-Numbers of participants achieving Minimal clinically important difference in HADS-D compared between baseline and follow up assessment.
0,8weeks
Number of Participants Reporting Change in Chronic Obstructive Pulmonary Diseases Assessment Test (CAT)
Time Frame: 0,8weeks
Chronic Obstructive Pulmonary diseases Assessment Test (CAT score)-Numbers of participants achieving Minimal clinically important difference in CAT score compared between baseline and follow up assessment.
0,8weeks
Number of Patients Reporting Change in Physical Activity
Time Frame: 8 weeks
Pedometer- Number of step counts
8 weeks
Number of Participants With Change in Quadriceps Muscle Strength
Time Frame: 0,8 weeks
Handheld Muscle testing- Number of participants achieving Minimal clinical important difference in quadriceps muscle strength compared between baseline and follow up assessment
0,8 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Vijayaragavan Padmanaban, MPT, Imperial Healthcare NHS Trust

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 14, 2016

Primary Completion (Actual)

June 19, 2017

Study Completion (Actual)

December 30, 2017

Study Registration Dates

First Submitted

February 23, 2016

First Submitted That Met QC Criteria

March 8, 2016

First Posted (Estimate)

March 14, 2016

Study Record Updates

Last Update Posted (Actual)

March 30, 2021

Last Update Submitted That Met QC Criteria

March 3, 2021

Last Verified

March 1, 2021

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Obstructive Pulmonary Diseases

Clinical Trials on Pulmonary Rehabilitation

Subscribe